吗替麦考酚酯对预防视神经脊髓炎谱系疾病复发的临床观察  

Clinical Observation of Mycophenolate Mofetil in Preventing the Recurrence of Diseases of Optic Nerve Myelitis Spectrum

作　　者：王丽丽[1] WANG Li-li(Henan People＇s Hospital Department of Neurology, Zhengzhou Henan 450000, Chin)

机构地区：[1]河南省人民医院神经内科,河南郑州450000

出　　处：《药品评价》2018年第10期37-39,60,共4页Drug Evaluation

摘　　要：目的:探讨吗替麦考酚酯能否有效预防视神经脊髓炎谱系疾病的复发。方法:回顾性分析2015.07—2016.07来我院就诊的38例视神经脊髓炎谱系统疾病患者的病例资料,按照患者在疾病缓解期是否服用吗替麦考酚酯进行预防而分为治疗时段和无治疗时段,比较不同时段的复发率、停药原因以及通过扩展残疾状态量表(Expanded disability status scale,EDSS)评价疾病的严重程度。结果:治疗时段的复发率为7.89%,显著低于无治疗时段的复发率52.63%,差异有统计学意义,P<0.05;视神经脊髓炎谱系疾病患者停药的原因主要有经济因素、复发、白细胞下降、肌酐酶升高;患者吗替麦考酚酯治疗后首次缓解期EDSS评分为(4.60±0.56)分,显著高于最后缓解期的(2.47±0.31)分,差异有统计学意义,P<0.05。结论:吗替麦考酚酯能有效预防视神经脊髓炎谱系疾病的复发,且能改善患者神经功能缺失的症状,值得临床推广应用。Objective： To investigate whether mycophenolate mofetil can effectively prevent the recurrence of spectrum diseases of the optic nerve myelitis. Methods： 38 cases of patients with optic nerve myelitis spectrum system disease in our hospital from 2015.07 to 2016.07 were retrospectively analyzed. According to whether the patients were treated during the remission period, they were divided into treatment period and no treatment period. Recurrence rates at different times, reasons for discontinuation were compared, and disease severity was assessed by expanding the Disability Status Scale（EDSS）. Results： The recurrence rate was 7.89% in the treatment period, which was significantly lower than the recurrence rate 52.63% in the no-treatment period（P〈0.05）. The main reasons for discontinuation of NMOSD patients were as follows： There were economic factors, recurrence, leukopenia, and elevated creatinine enzyme; the patient knew that the first remission EDSS score was（4.60±0.56） points after treatment, which was significantly higher than the final remission（2.47±0.31） points. The difference was statistically significant（P〈0.05）. Conclusion： Mycophenolate mofetil can effectively prevent the recurrence of spectrum diseases of optic nerve and myelitis, and can improve the symptoms of neurological deficit in patients. It is worthy of clinical application.

关 键 词：吗替麦考酚酯 神经脊髓炎谱系疾病 复发 预防 

分 类 号：R971[医药卫生—药品]